A machine learning-based algorithm to predict which cancer patients benefit from immunotherapy

October 30, 2019

Scientists at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with the Centre for Genomic Regulation (CRG) and Radboud University, have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy.

Mutations in our DNA can disrupt protein synthesis, sometimes causing truncated proteins which don't work as intended. Known as nonsense mutations, these types of alterations can give rise to hereditary diseases and different types of cancer. To keep the number of truncated proteins to a minimum, human cells recognise and remove RNAs with nonsense mutations through a quality control process known as nonsense-mediated mRNA decay (NMD).

To better understand the effect of NMD on human disease, researchers built NMDetective, a tool describing every possible nonsense mutation that can occur in the human genome. Developed by large-scale statistical analyses based on machine learning, the algorithm identifies which mutations in the genome are susceptible to NMD.

As described today in Nature Genetics, scientists used NMDetective to analyse thousands of genetic variants that give rise to hereditary diseases in humans. "We were surprised to observe that, in many cases, NMD activity was predicted to lead to a greater severity of the disease," says Fran Supek, ICREA researcher, head of the Genome Data Science laboratory at IRB Barcelona and leader of the team that built the tool.

The results of the study suggests that pharmacological NMD inhibition could slow the progression of many different genetic diseases. To distinguish which patients would benefit from this therapy, it is necessary to apply a precision medicine approach to determine the mutation responsible for the disease and the effect of NMD on this mutation, and this is precisely where NMDetective comes into play.

Researchers also studied the role of NMD in cancer and the interaction between the tumour and the immune system. "We discovered that NMD activity is important for the prediction of successful outcome of immunotherapy in cancer," explains Supek. Researchers found NMD hides mutations that would otherwise trigger the immune system. Therefore, NMDetective can be used to analyse the mutations present in the tumour, in order to better distinguish between cancer patients that respond to immunotherapy from those who do not respond to immunotherapy.

"Tumours are riddled with genetic mutations that should make all sorts of weird proteins. The immune system should pick these up, identifying the cells gone wrong and destroying them," says Ben Lehner, a researcher at the Centre for Genomic Regulation who also took party in the study. "But many of these weird proteins never actually get made because of NMD."

"This algorithm can distinguish which mutations will and won't trigger this error-checking system. What's exciting is that drugs that block NMD already exist, which could be used in conjunction with other treatments to help the immune system better recognise tumour cells," explains Lehner,.

"Here we see an example where publicly available cancer genomics data can be 'reused' through machine learning approaches to better understand biological processes such as NMD," says lead author Rik Lindeboom, a researcher at Radboud University in the Netherlands. "What makes this study especially exciting, is that we could directly translate this fundamental research into insights that are relevant for clinicians and patients."

This study has been funded by the HYPER-INSIGHT and IR-DC grants from the European Research Council, by the Dutch Oncode Institute, by the Ministry of Science, Innovation and Universities (previously MINECO), the Bettencourt Schueller Foundation and AGAUR.

Reference article Rik G.H. Lindeboom, Michiel Vermeulen, Ben Lehner & Fran Supek The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy Nature Genetics (2019) DOI: 10.1038/s41588-019-0517-5
-end-


Institute for Research in Biomedicine (IRB Barcelona)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.